GlassScriptPhysician profile
Ousamma I Dagher
NPI 1710183165
$6,377.20
in general payments reported to CMS, 2019-2025
24 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $502 · 2021: $735 · 2022: $744 · 2023: $762 · 2024: $748 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Travel and Lodging: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.81 |
| Travel and Lodging | $919.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,089.00 | 2019-2024 | Repatha |
| Endologix LLC | $1,061.55 | 2025 | Endocross Device, Torus Stent Graft System |
| Abbott Laboratories | $624.73 | 2020-2025 | Esprit, Jeti Peripheral Catheter, Gallant |
| Abiomed | $250.57 | 2025 | |
| Stryker Corporation | $168.50 | 2025 | Venacore Thrombectomy Catheter |
| E.R. Squibb & Sons, L.L.C. | $148.96 | 2021-2024 | Camzyos |
| Pfizer INC. | $146.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $117.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $109.75 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $105.93 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.17 | 2019-2023 | Lifevest |
| Shockwave Medical, INC | $58.44 | 2025 | |
| Biotronik INC. | $55.99 | 2025 | Amvia Edge, Pamira |
| Medtronic Vascular, INC. | $48.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.92 | 2020-2024 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $48.73 | 2020-2023 | Flexitouch Plus, Entre Plus |
| Bayer Healthcare Pharmaceuticals INC. | $47.44 | 2025 | |
| Esperion Therapeutics, INC. | $27.51 | 2021 | |
| Merck Sharp & Dohme LLC | $23.68 | 2021 | |
| Depuy Synthes Sales INC. | $22.08 | 2019 | |
| Boston Scientific Corporation | $21.58 | 2024 | Watchman Flx |
| Scpharmaceuticals INC. | $18.48 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.18 | 2025 | Farxiga |
| Vivaquant INC, Dba Rhythm Express | $14.03 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ousamma Dagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.